IL2 and breast cancer: Although follow-up Phase II studies demonstrated that daily low dose (1.75 × 106 IU/m2/day) subcutaneous IL-2 was better tolerated in relapsed non-Hodgkin’s lymphoma and breast cancer patients and expanded cytotoxic T cells, no improvement in patient outcomes was reported.